Italia markets close in 1 hour 18 minutes
FTSE MIB
33.294,25 +386,20 (+1,17%) Dow Jones
38.796,30 +18,20 (+0,05%) Nasdaq
17.871,30 +14,28 (+0,08%) Nikkei 225
38.482,11 +379,67 (+1,00%) Petrolio
81,16 +0,83 (+1,03%) Bitcoin EUR
60.083,47 -727,32 (-1,20%)
NBIX Oct 2024 135.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 12:00PM EDT. Mercato aperto.
| Chiusura precedente | 15,51 |
| Aperto | 15,80 |
| Denaro | 13,00 |
| Domanda | 17,50 |
| Prezzo d'esercizio | 135,00 |
| Scadenza | 2024-10-18 |
| Min-Max giorno | 15,51 - 15,80 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 10 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.